MPLT vs NGNE: fair value comparison
MapLight Therapeutics, Inc. and Neurogene Inc. · Updated 2026-10-19
MPLT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NGNE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MPLT currently ranks higher by quality score.
| MPLT | NGNE | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $7.70 | $23.25 |
| 12-month range | $7.70–$39.80 | $16.37–$42.84 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #253 of 301 Healthcare | #254 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: MPLT fair value analysis · NGNE fair value analysis